Inhaled Bevacizumab: A case study for delivery to the lung

Bevacizumab is a monoclonal antibody VEGF-inhibitor approved for treatment of cancers, including lung and colon. The goal of this study was to perform a real-time stability study of spray-dried bevacizumab dry powder formulation out to 24 months. 

Download the poster, presented at RDD Europe 2023, to learn more.

You may also be interested in:
Small Molecules
Inhalation
Oral Drug Products
Spray Dried Dispersions
Author(s):
Kimberly Shepard, Ph.D.
Director, Respiratory Delivery
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
GS Effex® Cell Line - full image
Technical/Service brief
GS Effex® Cell Line for Enhanced Antibody Effector Function
GS Effex® derived from Lonza's leading GS Xceed® cell line, has been engineered to lack the enzyme...
Technical/Service brief
XS Technologies® Microbial Platform for Protein Expression Brochure
XS Technologies® are the microbial expression systems for today’s therapeutics. While...
Article
Navigating the Future of Bioconjugates and ADCs: An Expert Q&A with Iwan Bertholjotti
Lonza_Bend_SFSLab.017
Webinar (on-demand)
Unlock the future of drug development with PBBM and solid form screening for early-phase success
Struggling with poor bioavailability in your early-phase drug candidates? You're not alone. Low...
Lonza_Bend_EarlyPhaseLab33
Article
Empowering smarter decisions in drug development through modeling, AI and scientific expertise
Bispecific vial hand
Webinar (on-demand)
Building Better Biologics: Early strategies for optimizing the progression of biotherapeutic...
The early stages of biologic drug development are critical to long-term clinical and commercial...
Poster
Cocoon® platform demonstrates compatibility with off-the-shelf process analytical technologies
The Lonza Cocoon® Platform uniquely addresses the challenges of automated cell therapy manufacturing...
Poster
End-to-end production of t cells on the Cocoon® platform, using buoyancy-activated cell sorting...
High-purity, viable T cell isolation is essential for consistent upstream processing of CAR-T cell...
Technical/Service brief
Elevate expression with the GSquad® Pro vector system
At Lonza, we continually invest in innovation covering all platform elements to help ensure that we...
Technical/Service brief
Room to Grow: Exploring the Capabilities of 15,000L Microbial Manufacturing
Scaling microbial processes requires more than capacity - it demands precision, flexibility, and...
Technical/Service brief
Rapid Cocoon® CAR-T: rapid manufacturing of CAR-T cells with integrated selection in the Cocoon®...
Integrated magnetic separation capabilities enrich for a pure T cell input To enable rapid...
DPS
White paper
Industry-backed, data-driven approaches to enhancing container closure integrity
Container closure integrity (CCI) is central to ensuring product quality and patient...